Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Tidewater Inc (TDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Tidewater Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Tidewater Inc trades at $74.39 (market cap $3.65B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 10.9× Tidewater Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | TDW | |
|---|---|---|
Market Cap | $39.89B | $3.65B |
Sector | Health | Utilities |
52-Week High | $491.22 | $91.12 |
52-Week Low | $278.09 | $46.32 |
Enterprise Value | $38.15B | $3.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Tidewater (TDW) trades at $73.37, up 3.84% with bullish technical signals from moving averages. The company maintains strong profitability with 22.16% net income margin and 24.03% ROE, though recent Q1 2026 earnings missed estimates. Valuation appears reasonable with P/E of 12.37 and EV/EBITDA of 9.15. Recent news includes FTAI Infrastructure's acquisition of Tidewater Logistics and mixed analyst sentiment.
The outlook remains cautiously optimistic given strong fundamentals but tempered by recent earnings misses. Investment opportunity lies in reasonable valuation and sector positioning, while risks include execution challenges and energy market volatility. Analyst consensus leans neutral with 61.54% hold ratings, suggesting balanced risk-reward profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
